AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Adaptive Biotechnologies Corporation
Video analysis: ADPT
All videosNo video analysis for this stock yet. Request one from our team.
News: ADPT
Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
SEATTLE, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY.
Algert Global LLC Has $2.83 Million Position in Adaptive Biotechnologies Corporation $ADPT
Algert Global LLC decreased its position in Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 63.7% during the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 131,830 shares of the company's stock after selling 230,880 shares during the quarter. Algert Global LLC owned 0.08% of Adaptive
Adaptive Biotech co-founder raises $15M for new startup to rethink how AI trains on science
Harlan Robins spent years as the co-founder and chief scientific officer of Adaptive Biotechnologies, helping build massive datasets to decode
Dimensional Fund Advisors LP Cuts Stock Holdings in Adaptive Biotechnologies Corporation $ADPT
Dimensional Fund Advisors LP lowered its stake in shares of Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 86.4% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 188,338 shares of the company's stock after selling 1,194,586 shares during the quarter. Dimensional
Adaptive Biotechnologies: The MRD Separation Creates A Pure-Play Compounder
Adaptive Biotechnologies (ADPT) is transitioning to a pure-play MRD diagnostics company, with the spin-off of Immune Medicine revealing strong underlying profitability. MRD revenue grew 49% year-over-year (excluding milestones), sequencing gross margins exceeded 70%, and adjusted EBITDA margin reached 14%, supporting a high-growth, high-quality earnings profile. Refinancing eliminated a 5% perpetual revenue burden, while the planned separation of Immune Medicine should clarify earnings and remove $6M in quarterly adjusted EBITDA losses.
Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue?
Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Adaptive Biotechnologies Corporation (ADPT) Q2 2026 Earnings Call Transcript
Adaptive Biotechnologies Corporation (ADPT) Q2 2026 Earnings Call Transcript
Adaptive Biotechnologies (ADPT) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
